[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-346090-105":3,"doc-detail-346090-en":81,"detail-sidebar-cat-0-en-105":115},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","5-fluorouracil-cream-for-actinic-keratoses-first-report-of-efficacy-and-tolerability-in-a-person-living-with-human-immunodeficiency-virus-infection","5-Fluorouracil Cream for Actinic Keratoses - First Report of Efficacy and Tolerability in a Person Living With Human Immunodeficiency Virus Infection","","Actinic keratosis (AK) is a common premalignant skin condition linked to chronic ultraviolet exposure, with increased risk of progression to cutaneous squamous cell carcinoma (cSCC). Prevalence rises with age and is shaped by fair skin phototype and immunosuppression. People living with HIV face impaired immune surveillance, yet evidence on optimal AK treatment in this population remains limited. A 70-year-old man with well-controlled HIV received topical 5-fluorouracil (4%) once daily for 28 days, achieving complete clinical clearance by 3 months.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/5-fluorouracil-cream-for-actinic-keratoses-first-report-of-efficacy-and-tolerability-in-a-person-living-with-human-immunodeficiency-virus-infection/346090/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/5-fluorouracil-cream-for-actinic-keratoses-first-report-of-efficacy-and-tolerability-in-a-person-living-with-human-immunodeficiency-virus-infection/346090.png","ImageObject",300,407,{"name":42,"@type":43},"Aurelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the clinical significance of actinic keratosis in people living with HIV?","Question",{"text":63,"@type":64},"AK is a premalignant condition with a risk of progressing to cutaneous squamous cell carcinoma (cSCC). In people living with HIV, impaired immune surveillance increases oncologic risk, making early diagnosis and effective management important.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which treatment regimen was used in the case report?",{"text":68,"@type":64},"The patient with multiple facial actinic keratoses received topical 5-fluorouracil (5-FU) 4% cream once daily for 28 days after prior temporary improvement from treatments such as cryotherapy, diclofenac gel, and tirbanibulin.",{"name":70,"@type":61,"acceptedAnswer":71},"What tolerability and outcomes were observed after 5-FU 4% therapy?",{"text":72,"@type":64},"During treatment, the patient developed a moderate inflammatory reaction with erythema and pruritus, expected and not requiring discontinuation. At 3-month follow-up, complete clinical clearance of the lesions was achieved.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},346090,1790125875,{"code":4,"msg":82,"data":83},"success",{"doc_id":79,"user_id":84,"nickname":42,"user_avatar":85,"doc_module":4,"category_id":86,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":87,"file_id":88,"file_url":89,"file_type":90,"file_size":91,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":33,"language":92,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":93,"faqs":94,"seo_title":95,"seo_description":12,"update_tm":96,"read_time":97,"preview_page_count":33,"preview_urls":98},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728",8,"Clinical Case Reports  \nCASE REPORT  OPEN ACCESS   \n4% 5-Fluorouracil Cream for Actinic Keratoses: First Report of Efficacy and Tolerability in a Person Living With Human Immunodeficiency Virus Infection  \nGloria Hoxhallari1 | Aurelio Portincasa2 | Nicola Fini2 | Vincenzo Verdura2  | Liberato Roberto Cecchino2  |  \nFedele Lembo2 | Sergio Lo Caputo3 | Domenico Bonamonte4  | Caterina Foti4  | Francesco Drago5 | Giulia Ciccarese4   \n1Department of Dermatology and Venereology, Mother Teresa University Hospital Center, Tirana, Albania | 2Unit of Reconstructive and Plastic Surgery, Department of Clinical and Experimental Medicine, Ospedali Riuniti di Foggia and University of Foggia, Foggia, Italy | 3Infectious Diseases Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy | 4Section of Dermatology, Department of Precision and Regenerative  \nMedicine and Jonian Area, University Aldo Moro of Bari, Bari, Italy | 5Section of Dermatology, Casa di Cura Villa Montallegro, Genoa, Italy Correspondence: Giulia Ciccarese ([giulia.ciccarese@unifg.it](giulia.ciccarese@unifg.it); [giulia.ciccarese@uniba.it](giulia.ciccarese@uniba.it))  \nReceived: 9 April 2026 | Revised: 15 July 2026 | Accepted: 20 August 2026  \nKeywords: 5 fluorouracil cream | actinic keratoses | cutaneous squamous cell carcinoma | human immunodeficiency virus infection (HIV) | people living with HIV  \nABSTRACT  \nActinic keratosis (AK) is a common premalignant skin condition associated with chronic ultraviolet exposure and an increased risk of progression to cutaneous squamous cell carcinoma (cSCC) . Its prevalence rises with age and is influenced by multiple factors, including fair skin phototype and immunosuppression. People living with human immunodeficiency virus (HIV) are at increased risk of cSCC due to impaired immune surveillance, highlighting the importance of early diagnosis and effective management of AK in this population. However, data on optimal treatment strategies in individuals with HIV remain limited. Among available therapies, topical 5-fluorouracil (5-FU) is considered one of the most effective field-directed treatments. We describe the case of a 70-year-old man with well-controlled HIV infection who presented with multiple facial actinic keratosesin a field of cancerization. The patient had previously undergone several treatments, including cryotherapy, diclofenac gel, and tirbanibulin, with only temporary improvement. Given the extent of the lesions and prior therapeutic failure, topical 5-FU 4% cream was initiated once daily for 28 days. During treatment, the patient developed a moderate inflammatory reaction characterized by erythema and pruritus, which was expected and did not require discontinuation. At the 3-month follow-up, complete clinical clearance of the lesions was achieved. This case supports the efficacy and acceptable tolerability of topical 5-FU 4% in the treatment of AK in a patient living with HIV, even after previous treatment failure. The results are consistent with existing evidence supporting the use of 5-FU as a first-line field therapy. Given the increased oncologic risk in immunocompromised patients, timely and effective treatment of AK is essential. Nevertheless, the limited evidence available in this specific population underscores the need for further prospective studies to better define management strategies and long-term outcomes.  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2026 The Author(s). Clinical Case Reports published by John Wiley & Sons Ltd.  \nClinical Case Reports, 2026; 14:e73428 1 of 4  \n[https://doi.org/10.1002/ccr3.73428](https://doi.org/10.1002/ccr3.73428)  \nKey Clinical Message  \nGiven the increased oncologic risk in immunocompromised patients, timely, and effective treatment of AK is essential. Our case report supports ","cbCaitDlzKQ6OiRP","https://ap.wps.com/l/cbCaitDlzKQ6OiRP","pdf",472251,"English","# Abstract\n## Case description and treatment outcome\n## Introduction and clinical background","[{\"question\":\"What is the clinical significance of actinic keratosis in people living with HIV?\",\"answer\":\"AK is a premalignant condition with a risk of progressing to cutaneous squamous cell carcinoma (cSCC). In people living with HIV, impaired immune surveillance increases oncologic risk, making early diagnosis and effective management important.\"},{\"question\":\"Which treatment regimen was used in the case report?\",\"answer\":\"The patient with multiple facial actinic keratoses received topical 5-fluorouracil (5-FU) 4% cream once daily for 28 days after prior temporary improvement from treatments such as cryotherapy, diclofenac gel, and tirbanibulin.\"},{\"question\":\"What tolerability and outcomes were observed after 5-FU 4% therapy?\",\"answer\":\"During treatment, the patient developed a moderate inflammatory reaction with erythema and pruritus, expected and not requiring discontinuation. At 3-month follow-up, complete clinical clearance of the lesions was achieved.\"}]","5-Fluorouracil Cream for Actinic Keratoses - First Report of Efficacy and Tolerability in a Person Living With Human Immunodeficiency Virus Infection | PDF",1790060048,10,[99,103,107,111],{"page_no":22,"url":100,"width":101,"height":102},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/595c1a3cf6d90f8c97eab291d75cfe84.webp",983,1291,{"page_no":26,"url":104,"width":105,"height":106},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/08aa2c8cd55bdaf2721c11637f5cc01f.webp",982,1290,{"page_no":30,"url":108,"width":109,"height":110},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c0b25209c607c53843523764d2b50d3a.webp",981,1289,{"page_no":33,"url":112,"width":113,"height":114},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/53a23c2ecdb2204e7dcc4bfb5a76b1e5.webp",980,1287,{"code":4,"msg":82,"data":116},[117,121,125,129,134,139,144,147,152,155,158],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":118,"show_sort_weight":119,"slug":120},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":122,"show_sort_weight":123,"slug":124},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":126,"show_sort_weight":127,"slug":128},"Exam",70,"exam",{"id":130,"doc_module":4,"doc_module_name":25,"category_name":131,"show_sort_weight":132,"slug":133},5,"Comic",60,"comic",{"id":135,"doc_module":4,"doc_module_name":25,"category_name":136,"show_sort_weight":137,"slug":138},6,"Technology",50,"technology",{"id":140,"doc_module":4,"doc_module_name":25,"category_name":141,"show_sort_weight":142,"slug":143},7,"Healthcare",40,"healthcare",{"id":86,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":145,"slug":146},30,"research-report",{"id":148,"doc_module":4,"doc_module_name":25,"category_name":149,"show_sort_weight":150,"slug":151},9,"Religion & Spirituality",20,"religion-spirituality",{"id":150,"doc_module":4,"doc_module_name":25,"category_name":153,"show_sort_weight":150,"slug":154},"World Cup","world-cup",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":156,"show_sort_weight":97,"slug":157},"Lifestyle","lifestyle",{"id":159,"doc_module":4,"doc_module_name":25,"category_name":160,"show_sort_weight":130,"slug":161},19,"General","general"]